Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS by Levy, Adrian R et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Lipids in Health and Disease
Open Access Research
Changes in lipids over twelve months after initiating protease 
inhibitor therapy among persons treated for HIV/AIDS
Adrian R Levy*1,2, Lawrence McCandless2, P Richard Harrigan3, 
Robert S Hogg1,3, Greg Bondy4, Uchenna H Iloeje5, Jayanti Mukherjee5 and 
Julio S Montaner3,6
Address: 1Department of Health Care and Epidemiology, University of British Columbia (UBC), Vancouver, Canada, 2Centre for Health 
Evaluation & Outcome Sciences, St. Paul's Hospital, Vancouver, Canada, 3BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, 
Canada, 4St. Paul's Hospital HIV Metabolic and Lipid Clinic, Vancouver, Canada, 5Bristol-Myers Squibb, Wallingford, Connecticut, USA and 
6Department of Medicine, UBC, Vancouver, Canada
Email: Adrian R Levy* - alevy@interchange.ubc.ca; Lawrence McCandless - lawrence@stat.ubc.ca; P Richard Harrigan - richard@hivnet.ubc.ca; 
Robert S Hogg - bobhog@hivnet.ubc.ca; Greg Bondy - gbondy@providencehealth.bc.ca; Uchenna H Iloeje - uchenna.iloeje@bms.com; 
Jayanti Mukherjee - jayanti.mukherjee@bms.com; Julio S Montaner - julio.montaner@hivnet.ubc.ca
* Corresponding author    
HIV/AIDSprotease inhibitorscholesteroltriglyceridescardiovascular disease
Abstract
Background: Protease inhibitors are known to alter the lipid profiles in subjects treated for HIV/AIDS. However, the
magnitude of this effect on plasma lipoproteins and lipids has not been adequately quantified.
Objective: To estimate the changes in plasma lipoproteins and triglycerides occurring within 12 months of initiating PI-based
antiretroviral therapy among HIV/AIDS afflicted subjects.
Methods: We included all antiretroviral naïve HIV-infected persons treated at St-Paul's Hospital, British Columbia, Canada,
who initiated therapy with protease inhibitor antiretroviral (ARV) drugs between August 1996 and January 2002 and who had
at least one plasma lipid measurement. Longitudinal associations between medication use and plasma lipids were estimated using
mixed effects models that accounted for repeated measures on the same subjects and were adjusted for age, sex, time
dependent CD4+ T-cell count, and time dependent cumulative use of non-nucleoside reverse transcriptase inhibitors and
adherence. The cumulative number of prescriptions filled for PIs was considered time dependent. We estimated the changes in
the 12 months following any initiation of a PI based regimen.
Results: A total of 679 eligible subjects were dispensed nucleoside analogues and PI at the initiation of therapy. Over a median
47 months of follow-up (interquartile range (IQR): 29–62), subjects had a median of 3 (IQR: 1–6) blood lipid measurements.
Twelve months after treatment initiation of PI use, there was an estimated 20% (95% confidence interval: 17% – 24%) increase
in total cholesterol and 22% (12% – 33%) increase in triglycerides.
Conclusions: Twelve months after treatment initiation with PIs, statistically significant increases in total cholesterol and
triglycerides levels were observed in HIV-infected patients under conditions of standard treatment. Our results contribute to
the growing body of evidence implicating PIs in the development of blood lipid abnormalities. In conjunction with the
predominance or men, high rates of smoking, and aging of the treated HIV-positive population, elevated lipoproteins and
triglycerides may mean that patients such as these are at elevated risk for cardiovascular events in the future.
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Introduction
Abnormalities in the lipid metabolism of persons infected
with human immunodeficiency virus (HIV), potentially
induced by the disease itself and the medications used for
treatment, were first reported in the early 1990s[1].
Reductions in high- (HDL) and low-density lipoprotein
(LDL) cholesterol were observed amongst persons
infected with HIV and increases in triglycerides were
observed among persons with AIDS[1]. Following the
introduction of protease inhibitors (PI), morphological
changes in fat distribution were reported. This was fol-
lowed by numerous reports of metabolic disturbances,
including glucose and lipid abnormalities presenting as
insulin resistance, impaired glucose tolerance, hyperglyc-
emia, type 2 diabetes mellitus [2-5], elevated serum trig-
lycerides, LDL and very low density lipoprotein
cholesterol, apolipoprotein B, E, and lipoprotein(a) [2-
4,6]. The combination of metabolic disturbances and
morphological changes are now described as the HIV-
related "lipodystrophy syndrome"[2,3].
Up to one-half of subjects treated with PIs have shown ele-
vated levels of triglycerides, total cholesterol (TChol),
LDL, insulin, and fasting glucose [7-10]. The onset of met-
abolic changes appears to occur soon after initiation of
treatment, often as quickly as within several weeks[11].
The high prevalence of disturbances of lipoproteins and
triglycerides, the rapidity of their onset, and large changes
that have been observed in randomized trials have led to
concern regarding the potential impact of PIs on the car-
diovascular health of persons with HIV/AIDS. However,
the direction and magnitude of changes in plasma lipo-
proteins and triglycerides induced by PIs has yet to be
quantified in an observational setting. The aim of this
study was to quantify the magnitude of change in lipopro-
tein and triglyceride levels over twelve months following
any initiation of PI-based treatment in a cohort of subjects
treated for HIV/AIDS in a large tertiary care institution.
Methods
We included all antiretroviral naïve HIV-infected persons
treated at St-Paul's Hospital, British Columbia (BC), Can-
ada, who initiated use of PIs between August 1996 and
January 2002. Plasma lipoprotein and triglyceride levels
were obtained from measurements taken over the course
of regular monitoring. Longitudinal effects of the impact
of PIs on lipoproteins and triglycerides were estimated
using statistical models that accounted for correlation due
to repeated measurements on the same individuals.
Study Setting and Population
In BC, antiretroviral drugs have been centrally distributed
at no cost to eligible HIV-infected individuals since
1986[12,13]. In October 1992, the HIV/AIDS Drug Treat-
ment Program became the responsibility of the BC Centre
for Excellence in HIV/AIDS. Since December 1996, the
mainstay of treatment for HIV/AIDS has been highly
active antiretroviral therapy (HAART) including two nucl-
eosides and either a PI or a non-nucleoside reverse tran-
scriptase inhibitor (NNRTI). Typically, HIV-infected
subjects receiving antiretroviral therapy are monitored by
physicians at intervals no longer than three months at
which time prescriptions are renewed or modified based
on clinical and laboratory parameters, and necessary lab-
oratory tests are conducted. This research received ethical
approval from the Institutional Review Board of Provi-
dence Health Care in BC.
Exposure to antiretroviral therapy for HIV/AIDS
At the BC Centre for Excellence in HIV/AIDS, records of
CD4+ T-cell counts and a profile of dispensed antiretrovi-
ral therapy are routinely maintained, including the: pre-
scription fill dates, medications prescribed, and amount
dispensed. Records of dispensed antiretroviral medica-
tions, (including nucleoside analogs, PI and NNRTI) were
used to determine the drugs dispensed and available to
each subject during each month of follow-up. Subjects
were considered unexposed until the first month that a PI
was dispensed. The exposure at the time of the lipid meas-
urement was calculated as the cumulative number of con-
secutive months of drug exposure up until and including
the month in which a measurement was taken. As we were
interested in estimating changes that occur in plasma lipo-
proteins and triglycerides within the first year after treat-
ment initiation, we included measurements with a
cumulative PI exposure up to a maximum of twelve
months. Subjects were considered unexposed thirty days
after the last PI was dispensed and, at that time, the cumu-
lative exposure was set to zero.
Plasma lipoproteins and triglycerides
Approximately one-half of HIV-infected patients in BC are
followed at one treatment centre located at St. Paul's Hos-
pital, a large teaching hospital in Vancouver. For these
subjects, in addition to virological testing, the hospital
laboratory records the results of plasma lipoproteins and
triglycerides. Subjects were routinely instructed to fast for
12 hours prior to the sample being drawn. Blood samples
were collected in 10-1 EDTA-coated vacutainer tubes.
Plasma was separated by centrifugation for 10 minutes at
2,000 revolutions per minute. TChol in the plasma was
determined using an enzymatic method[14] and plasma
triglyceride was determined as previously described[15].
HDL cholesterol was determined using a heparin manga-
nese precipitation of apo B-containing lipoproteins[16]
and LDL cholesterol was calculated using the Friedewald
formula[17,18].
For some subjects, the first lipid measurement was taken
prior to the dispensation of any antiretroviral drugLipids in Health and Disease 2005, 4:4 http://www.lipidworld.com/content/4/1/4
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("treatment naïve" baseline lipid measurements). Other
subjects had their first recorded plasma lipoproteins and
triglycerides after HAART was initiated (initiation lipid
levels).
Statistical analysis
We used linear mixed effects models[19] to estimate the
effect of PI-based HAART on changes in plasma lipopro-
teins and triglycerides over twelve months. As blood lipid
levels were always greater than 0, the responses were log
transformed prior to model fitting. Effect estimates were
obtained via restricted maximum likelihood estimation
using the R© function lme(.). An analysis of variance indi-
cated that simple parallel-line models, where the exposure
effect was assumed to be constant over subjects, could
adequately explain variation in the data compared to
more complex models with random slopes. To account
for correlated responses due to repeated measurements on
the same individual, the correlation structure of the
model was specified to include only a random intercept
for each subject.
The following explanatory variables were included in the
models: age, sex, and CD4+ T- cell count at PI initiation,
concomitant use of NNRTI, and a measure of adherence
to antiretroviral therapy. Exposure to NNRTI was consid-
ered time-dependent and quantified using the same algo-
rithm that was used to calculate time dependent PI
exposure. Adherence was calculated by dividing the
number of months of antiretroviral medications dis-
pensed by the number of months of follow-up in the first
twelve months after treatment initiation. Incomplete
adherence represents the gap between the time that the
previous medication supply ran out until the next refill
date, and/or until the last contact date with the program.
This method is reliably associated with both clinical out-
comes and un-timed drug level monitoring[20,21].
For each outcome and associated regression coefficient β,
the quantity exp(β)-1 represented the adjusted monthly
percent change in that plasma lipid fraction. These values
were annualized using the formula exp(12 × β)-1. Ninety
five percent confidence intervals (95% CI) for the effect
estimates were obtained using the standard error for each
regression coefficient.
Two sensitivity analyses were conducted. The first analysis
involved restricting the analysis to lipid measurements
which were taken on subjects prior to any change from
baseline antiretroviral therapy. The second sensitivity
analysis included only subjects who had lipid measure-
ments taken prior to initiation of therapy.
Results
There were 679 subjects who were eligible for analysis,
91% of whom were male (Table 1). The median age was
38 years at initiation of therapy and the median baseline
CD4+ T-CELL COUNT was 210 cells/mm3. All subjects
initiated therapy that included a nucleoside analog and a
PI.
Subjects were followed for a median of 47 months (Table
2). During that follow-up time, subjects had a mean of
73% of months in which a PI had been dispensed, with a
mean of 31 prescription refills. The mean adherence in the
first year was 89%, and the median adherence was 100%
indicating that more than one-half of subjects were dis-
pensed all their medications.
A total of 3,010 lipid measurements were used in the anal-
ysis, with 400 subjects having had two or more lipid
measurements during the course of follow-up. There were
a median of 3 (IQR 1–6) measurements per subject. The
median time between lipid measurements was 3 (IQR 2–
5) months for all subjects.
Table 3 shows the percentage change in plasma lipopro-
tein and triglyceride levels after 12 months of PI use, after
adjustment for age, sex, and CD4+ T- cell count at
initiation, concomitant use of NNRTI, and adherence. Sta-
tistically significant increases of about 20% were observed
in TChol, the lipoprotein fractions, and triglycerides.
The sensitivity analyses indicated that the models were
robust to changes in the sub-population studied and the
exposures that were included. In the analysis that
included subjects who had a baseline measurement prior
to start of HAART, a plasma profile prior to antiretroviral
therapy initiation showed a similar pattern but with wider
confidence intervals. In the analysis which was restricted
to lipid measurements taken on subjects prior to switch-
ing from baseline therapy, the effect estimates were simi-
lar to those in Table 3.
Table 1: Demographic and clinical characteristics at treatment 
program enrollement among 679 subjects treated with PI-based 
HAART initiation for HIV/AIDS at St Paul's Hospital, 
Vancouver, BC, August 1996 – January 2002
Characteristic*
Age (y)
Mean (SD) Median 39 (8.9) 38
Sex (% male) 91
Status (% alive) at end of follow-up 93
CD4 (cells/mm3)
Mean (SD) Median 255 (222) 210
Abbreviations: SD = Standard deviation; PI protease inhibitor.Lipids in Health and Disease 2005, 4:4 http://www.lipidworld.com/content/4/1/4
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Discussion
In patients treated for HIV infection with HAART in a nat-
uralistic setting, we observed that treatment with PIs was
estimated to result in 20% increases in the levels of total
cholesterol, HDL- and LDL-cholesterol and triglycerides
twelve months after treatment initiation. Our results con-
tribute to the growing body of evidence implicating PIs in
the development of blood lipid abnormalities[22] and are
in keeping with findings of randomized trials where a
change from PI-based HAART to NRTI- or NNRTI-based
HAART was associated with improvements in the lipid
profile[23]. The observed increases in LDL-cholesterol
and triglycerides were expected based on results reported
from randomized trials. The finding of an increase in
HDL-cholesterol has been reported only in some[24] but
not all randomized trials.
Low HDL levels and other forms of dyslipidemia, and dis-
turbances in glucose metabolism, as well as central obes-
ity, have been shown to be strong independent risk factors
for cardiovascular morbidity and mortality in the general
population[25,26]. Furthermore, the clustering of risk fac-
tors leads to greater cardiovascular morbidity and mortal-
ity than would be expected to occur in relation to each
component alone[25]. These factors, when considered
together, provide grounds to suspect that persons being
treated for HIV infection with PI are at an increased risk of
cardiovascular disease[8]. The increases in triglycerides
caused by use of PI is of concern because there is growing
evidence that these lipids are an independent risk factor
for cardiovascular disease[27,28].
Two large observational cohort studies, published in
2003, showed discrepant results regarding the risks of car-
diovascular disease among persons treated with
HAART[29,30]. A retrospective administrative claims
database study from the US Veteran's Affairs indicated
that there was no relation between the use of antiretroviral
therapy and the risk of cardiovascular or cerebrovascular
hospitalizations [29]. A prospective multi-country collab-
Table 2: Use of PIs among 679 subjects initiating PI-based HAART for HIV/AIDS at St Paul's Hospital, Vancouver, BC, August 1996 – 
January 2002
Characteristic*
Number of months between initiation of PI and end of observation, median (IQR)** 47 (29–62)
% of follow-up time with dispensed therapy mean (SD), median for PI 73 (30) 84
Mean (SD) number prescriptions for***
PI 31 (19)
% adherence in first year
mean (SD) 89 (21)
median (IQR) 100 (92 – 100)
Abbreviations: SD = Standard deviation; IQR = Interquartile range; NRTI = nucleoside reverse transcriptase inhibitors; PI protease inhibitor; 
NNRTI = non-nucleoside reverse transcriptase inhibitor
* PIs available during follow-up included: indinavir, nelfinavir, saquinavir, and ritonavir. All data taken from time of first therapy initiation (treatment 
program enrollement).
** Time between first dispensation of HAART (enrollment) and last date of follow-up.
*** All prescriptions are of 30 day duration
Table 3: Baseline plasma cholesterol and triglycerides and estimated percent changes after 12 months when using PI among 679 
subjects treated for HIV/AIDS at St Paul's Hospital, Vancouver, BC, August 1996 – January 2002
Number of measurements 
(subjects)
Mean lipid baseline 
measurements (SD)
% change* (95% CI)
TChol 1620 (529) 4.2 (1.0) 20 (17, 24)
HDL 1250 (419) 1.0 (0.3) 22 (15, 29)
LDL 677 (295) 2.5 (0.8) 12 (5, 20)
N-HDL 1247 (419) 3.1 (1.2) 20 (15, 26)
TRG 1743 (556) 1.9 (1.2) 22 (12, 33)
Abbreviations: PI protease inhibitor; TChol = total cholesterol; HDL = high-density lipoprotein cholesterol; LDL = low- density lipoprotein 
cholesterol; N-HDL = Non-HDL Cholesterol; TRG = triglycerides
* Adjusted for age, sex, and CD4+ cell count at first prescription for HAART, concomitant use of non-nucleoside reverse transcriptase inhibitor and 
adherence to antiretroviral therapy in the first year of treatmentLipids in Health and Disease 2005, 4:4 http://www.lipidworld.com/content/4/1/4
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orative study, with clinical events validation from eleven
cohorts of HIV-infected persons showed that the inci-
dence of myocardial infarction increased with longer
exposure to combination antiretroviral therapy[30].
This study has a number of features that add credence to
the results. First, while only based at one hospital, the
study population comprised about one-half of the treated
population in BC. The study sample had similar demo-
graphic composition (age and sex) and CD4+ T-cell count
at initiation of therapy as other treated subjects in the
province. We believe that these results are therefore gener-
alizable to PI-regimen treated HIV-infected patients in BC,
as well as to other target populations with similar demo-
graphic characteristics. Second, as all dispensed PIs and
other antiretroviral medications are paid for and recorded
centrally, there was complete information on all HAART
medications available to all study subjects. We adjusted
for adherence using each subjects' refill compliance in the
first year of treatment. Third, data on the plasma lipid pro-
file, including both lipoproteins and triglycerides, were of
high quality. The measurements, while lacking the feature
of being taken at uniformly spaced intervals as in closely
monitored system such as randomized trial, represent the
actual experience in an observational setting. Fourth, the
enrollment period lasted over five years, allowing a large
sample size. We employed repeated measures analyses to
account for the correlated structure of the data.
This study was also subject to several limitations. First,
lipid measurements were not collected in a predetermined
manner as is typical in a prospective research study. Con-
sequently, the timing of measurements was irregular and
not all lipid fractions were measured when blood was
drawn. Second, despite instructions some subjects may
not have fasted for the full 12 hour period prior to blood
draws. Non-fasting triglyceride measurements are still
useful for predicting cardiovascular disease and
death[31]. Third, other potent risk factors for changes in
lipid profiles such as family history and diet were not con-
sidered. It is possible but unlikely that the type of triple
therapy prescribed by physicians could have been influ-
enced by the belief that PIs may negatively impact lipid
levels, likely leading to an attenuation of the estimates.
Fourth, a number of factors contributed to a bias towards
underestimating the true changes: for some subjects base-
line values were not obtained prior to treatment initia-
tion; it was not possible to adjust for concomitant use of
lipid modifying agents such as statins because these data
were not available; subjects with large changes in their
lipid profiles may have been switched to another class;
and treatment interruptions would also have affected
exposure estimates. As a result of these limitations, the
actual changes in plasma lipoprotein and triglycerides
may be greater than reported in this study. Fifth, we
assumed that patients who stop therapy or skip a month
of therapy can be modelled as treatment naïve with
respect to any subsequent therapy. More sophisticated sta-
tistical techniques are available[32] for handling this lim-
itation, but appropriate software and resolution of
technical issues are still in the developmental stages.
Lastly, it is possible that the PI effect on lipids and triglyc-
eride levels is not a class effect. The recently introduced PI,
atazanavir sulfate, has been shown in several randomized
clinical trials not to adversely affect lipid levels [33-38].
Due to changes in the HAART regimen that occurred
because of resistance, non-compliance, or other reasons, it
was not possible to isolate the effect of individual PIs.
Over the period under study, most subjects initiating PI-
based HAART were prescribed either indinavir or
nelfinavir.
Treating PI-induced dyslipidemia
As PI-based HAART is very effective in increasing survival
in HIV-infected patients[39], discontinuing PI is undesir-
able, even in patients with dyslipidemia. However, as PI-
induced dyslipidemia is often asymptomatic and typically
occurs in younger patients whose baseline risk of cardio-
vascular disease is low, the need for primary prevention is
often under-appreciated in clinical practice[40]. When it
is recognized, rather than discontinuing or switching PI
therapy, one response is to initiate pharmacologic therapy
with statins and/or fibrates[41].
Statins have been shown to be effective drugs to prevent
cardiovascular disease in non-HIV patients[26]. While the
role of statins in preventing cardiovascular disease in HIV
patients remains to be demonstrated definitively, several
smaller randomized controlled trials that have shown that
these medications have beneficial effects on PI-induced
dyslipidemia [42]. Until recently, pravastatin was the pre-
ferred statin for treating PI-induced dyslipidemia because
it does not require metabolism by the cyp 3A4 system.
However, recent studies have shown that moderate lipid
lowering with pravastatin was less effective than intensive
lipid lowering with atorvastatin in reducing: progression
of atherosclerotic lesions [43] in patients requiring coro-
nary angiography; and death or major cardiovascular
events in patients with an acute coronary syndrome[44].
Atorvastatin is a powerful and effective statin, though
there are still only limited published studies with this
agent in HIV patients[45]. Because of metabolism by cyp
3A4, the dose of atorvastatin should be reduced one-half
in patients receiving PIs. Lovastatin and simvastatin
require metabolic activation by cyp 3A4 and should be
avoided in patients receiving PIs. Rosusvastatin, a recently
introduced statin has features that make it attractive for
treating patients with PI-induced dyslipidemias: it does
not require metabolism by the cyp 3A4 system and itLipids in Health and Disease 2005, 4:4 http://www.lipidworld.com/content/4/1/4
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effectively reduces LDL cholesterol. The safety and effec-
tiveness of rosuvastatin in reducing clinical outcomes in
HIV patients remain to be demonstrated.
Fibrates are effective in lowering triglycerides and increas-
ing HDL and have been shown to be effective in HIV
patients[42]. Despite the impact on plasma lipids and
triglycerides, only one trial has shown fibrates to reduce
clinical outcomes[46,47]. Therefore, the role of fibrates in
reducing cardiovascular disease outcomes remains to be
fully elucidated. The main role of fibrates is to reduce the
risk of pancreatitis associated with hypertriglyceridemia.
In HIV patients, gemfibrozil should be limited to mono-
therapy because of the risk for myopathy. Fenofibrate is
the preferred drug if combination therapy with a statin is
contemplated. The efficacy of other lipid lowering drugs
such as niacin and cholesterol transport blockers
(ezetimibe) remains to be demonstrated. Bile acid seques-
trants are contraindicated in patients receiving HAART.
We conclude that there was an estimated 20% increase in
lipoproteins and triglycerides in the first year after initiat-
ing PI-based antiretroviral therapy in HIV-infected
patients under conditions of standard treatment. Whether
these increases continue beyond one year is of considera-
ble interest because lipoproteins and triglycerides are
known risk factors for cardiovascular disease. In conjunc-
tion with the predominance or men, high rates of smok-
ing, and aging of the treated HIV-positive population,
elevated lipoproteins and triglycerides may mean that
patients such as these are at elevated risk for cardiovascu-
lar events in the future.
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